With Patholytix 3.0, Deciphex overcomes one of the last barriers to full-scale adoption of digital pathology. For the first time, users can review and score non-clinical studies on a single platform. The benefit is faster pathology reviews,...

Deciphex launches its Diagnostics as a service in the United States. DUBLIN, Ireland, September 7th, 2022— Deciphex, a leading provider of Digital Pathology software and services, announced today the launch of their Diagnexia service...

DUBLIN, Ireland, May 19th 2022— Deciphex, a leading provider of pathology software and services, announced today the closing of a $11.5 million Series B funding round. The round was led by ACT Venture Capital, with Charles River...

        WILMINGTON, MA and DUBLIN, Ireland March 30 2020 -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex, a leader in...

Deciphex, the leading global player in the provision of global preclinical digital pathology services, announced today that it has achieved certification against ISO 27001:2013, the premier global standard for Information Security Management...

The Patholytix preclinical solution aids improved process efficiency in preclinical toxicology by adopting a unique pattern recognition approach LONDON, U.K. -- Based on its recent analysis of the Global pre-clinical toxicology digital...